Stimulation of Suicidal Erythrocyte Death by Ceritinib-Treatment of Human Erythrocytes | Zendy

Abdulla Al Mamun Bhuyan | Zendy; Elena Signoretto | Zendy; Rosi Bissinger | Zendy; Florian Läng | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Stimulation of Suicidal Erythrocyte Death by Ceritinib-Treatment of Human Erythrocytes

Author(s) -

Abdulla Al Mamun Bhuyan,

Elena Signoretto,

Rosi Bissinger,

Florian Läng

Publication year - 2016

Publication title -

cellular physiology and biochemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.486

H-Index - 87

eISSN - 1421-9778

pISSN - 1015-8987

DOI - 10.1159/000453167

Subject(s) - ceritinib , phosphatidylserine , staurosporine , apoptosis , kinase , microbiology and biotechnology , biology , ceramide , protein kinase c , chemistry , biochemistry , anaplastic lymphoma kinase , medicine , phospholipid , lung cancer , membrane , malignant pleural effusion

The anaplastic lymphoma kinase (ALK) inhibitor ceritinib is utilized for the treatment of ALK positive non-small cell lung carcinoma. Side effects of the drug include decrease of blood hemoglobin concentration. Possible causes of anemia include stimulation of suicidal erythrocyte death or eryptosis, which is characterized by cell shrinkage and cell membrane scrambling with phosphatidylserine translocation to the erythrocyte surface. Signaling of eryptosis includes increase of cytosolic Ca2+ activity ([Ca2+]i), oxidative stress, ceramide, staurosporine sensitive protein kinase C, SB203580 sensitive p38 kinase, D4476 sensitive casein kinase 1, and zVAD sensitive caspases. The present study explored, whether ceritinib induces eryptosis and, if so, to shed light on the cellular mechanisms involved.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research